Defining Clinical Improvement in Adult and Juvenile Myositis.
about
Selected aspects of the current management of myositisMethods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) systematic reviewMeasures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-A systematic review of studies that aim to determine which outcomes to measure in clinical trials in childrenMetabolic abnormalities and cardiovascular risk factors in children with myositisDeveloping a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research.Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathiesThe Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.Methods of formal consensus in classification/diagnostic criteria and guideline development.Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation.Reliability of the adult myopathy assessment tool in individuals with myositisDevelopment of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use.Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conferenceNovel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in JapanA Historical Cohort Study on the Efficacy of Glucocorticoids and Riboflavin Among Patients with Late-onset Multiple Acyl-CoA Dehydrogenase Deficiency.Physical function assessment tools in pediatric rheumatologySkeletal Muscle Magnetic Resonance Imaging of the Lower Limbs in Late-onset Lipid Storage Myopathy with Electron Transfer Flavoprotein Dehydrogenase Gene Mutations.Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositisMyositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.Serum adipocytokine profile and metabolic syndrome in young adult female dermatomyositis patients.Are repeated single-limb heel raises and manual muscle testing associated with peak plantar-flexor force in people with inclusion body myositis?Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositisPredictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.Disease activity measures in paediatric rheumatic diseases2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric RheumatologyRituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015Muscle involvement in systemic sclerosis: points to consider in clinical trials.2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/PaediatriDevelopment of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric RheumatologyManual muscle testing and hand-held dynamometry in people with inflammatory myopathy: An intra- and interrater reliability and validity study.2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects
P2860
Q26738952-B2040E08-7620-4B46-9C17-63BFD368C148Q26824003-AE965489-2A57-41D9-9FCF-61C45C40BE76Q27021322-4AA2FAE8-6D36-40AF-B262-C08332B1AA73Q28472665-B9B48B4E-3F55-4DE4-A79A-2994F6DDABAAQ33602858-75F27A0A-C3F3-4ED5-A769-6FD2B272EFC9Q33962448-F7243F12-DCED-4435-8098-EBDE3BBE4328Q34019438-CEB35B13-0C47-4DAD-8FE1-CB80C55EFC04Q34074602-C2B44F40-F19A-48E6-9390-2F63485B21A5Q34242363-97050683-B95B-4AB7-9F0D-B17CFDE54850Q34644962-9A03179C-9CC3-42D7-996D-C0ED3110B797Q35091202-58A5740C-8435-4B93-9D8E-4FDE4A14A191Q35281980-1E819776-1D0B-4293-ACAD-F32C18DC2247Q35669132-5EDBE55A-6ECA-4022-86F9-CD11DF7622E1Q35755515-E7EED3EA-0128-40C8-9F81-BE6E848746EDQ35861235-2EF18E76-02DD-4D4B-82E7-E5290950BCE2Q36278027-20CEFE02-992D-42BE-9F07-BBE0B8782A73Q36559044-390B4421-B5E4-4C68-937C-9542FC3DCD8FQ36705436-F6EAA187-E784-4A5E-989F-C75B380B2F6CQ36737894-251117E6-93B1-4CC6-ABEE-A81A117B2188Q37011336-17892A66-8463-472A-9AC4-13998C6009AAQ37080228-FDA85D9E-0D89-406C-B6A4-FD2DA536A005Q37368405-F27A7D9C-17E3-4C17-8A9F-947CE77C8922Q37475947-00D5DC2F-371E-4DD0-9933-9B2205B6CDC2Q37522796-231E1CBC-8599-494C-BCDF-9A1ECC0113FBQ37681219-DC681732-0157-446B-B3E7-58C43F4F8C5CQ37689900-F4D17245-26AE-4A47-840A-749528EA209EQ37704799-92D62B81-6161-4E5B-98C2-D7E2A1C757E2Q38148751-49822019-905A-49A6-891A-CD1AB6F7DED9Q38849144-AE9C2F80-A3BC-4245-8F68-B57953834192Q38849148-5CCADCE2-48D2-4C22-A872-3D0B9745A35CQ40697549-166DBC31-2EA7-4480-9879-5D29E920F28DQ42365042-C6239E4D-D3E2-4957-A76E-0B3CEE3966D7Q46256178-3AC576D7-85D7-4642-931D-AF12122A35D6Q46815762-895CB6C7-C80A-4408-8462-1D5066B33988Q47689325-C6B4CCB8-F3FB-436E-96BE-327064C8303BQ47924181-084F6A23-FD85-4B50-9217-5D8D7D8FA3D9Q55078313-BDC47FA9-438B-461C-9F61-C76D4CA8BB60Q58490673-194A7C11-9F21-4364-ADC4-D92F80140C7E
P2860
Defining Clinical Improvement in Adult and Juvenile Myositis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Defining Clinical Improvement in Adult and Juvenile Myositis.
@ast
Defining Clinical Improvement in Adult and Juvenile Myositis.
@en
type
label
Defining Clinical Improvement in Adult and Juvenile Myositis.
@ast
Defining Clinical Improvement in Adult and Juvenile Myositis.
@en
prefLabel
Defining Clinical Improvement in Adult and Juvenile Myositis.
@ast
Defining Clinical Improvement in Adult and Juvenile Myositis.
@en
P2093
P50
P1476
Defining Clinical Improvement in Adult and Juvenile Myositis
@en
P2093
Clarissa Pilkington
Edward H Giannini
International Myositis Assesment and Clinical Studies Group
Peter A Lachenbruch
P304
P407
P577
2003-03-01T00:00:00Z